Case of anterior uveitis after intravitreal injection of bevacizumab

被引：34

作者：

Pieramici, Dante J. ^{[1
]}

Avery, Robert L. ^{[1
]}

Castellarin, Alessandro A. ^{[1
]}

Nasir, Ma'An A. ^{[1
]}

Rabena, Melvin ^{[1
]}

机构：

[1] Calif Retina Res Fdn, Santa Barbara, CA 93103 USA

来源：

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 2006年 / 26卷 / 07期

关键词：

bevacizumab (Avastin); age-related macular degeneration; complications; choroidal neovascularization; episcleritis; inflammation; ranibizumab (Lucentis); uveitis;

D O I：

10.1097/01.iae.0000234629.22614.cd

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

[No abstract available]

引用

页码：841 / 842

页数：2

共 4 条

[1] Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].

Avery, RL ;

Pieramici, DJ ;

Rabena, MD ;

Castellarin, AA ;

Nasir, MA ;

Giust, MJ .

OPHTHALMOLOGY, 2006, 113 (03) :363-372

[2] Ranibizumab for treatment of neovascular age-related macular degeneration - A phase I/II multicenter, controlled, multidose study [J].

Heier, JS ;

Antoszyk, AN ;

Pavan, PR ;

Leff, SR ;

Rosenfeld, PJ ;

Ciulla, TA ;

Dreyer, RF ;

Gentile, RC ;

Sy, JP ;

Hantsbarger, G ;

Shams, N .

OPHTHALMOLOGY, 2006, 113 (04) :633-642

[3] Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration [J].

Rosenfeld, PJ ;

Schwartz, SD ;

Blumenkranz, MS ;

Miller, JW ;

Haller, JA ;

Reimann, JD ;

Greene, WL ;

Shams, N .

OPHTHALMOLOGY, 2005, 112 (06) :1048-1053

[4]

2005, AM SOC RET SPEC M JU

← 1 →